// author archive

Carl-Henrik Brogren

Carl-Henrik Brogren has written 24 posts for ImmunoSigns

Bioluminescent recombinant IC2 developed in collaboration with Stanford University

Stanford University. Millegen Biotech and University of Copenhagen has collaborated supported by Juvenile Diabetes Research Foundation in the development of a new recombinant bioluminescent fusion protein scFv-Gluc, with the aim of testing the new format for in vivo noninvasive biolumeniscent imaging (BLI) of beta-cells in whole animals and pancreas tissue. The first fusion protein is […]

IC2 expected on the international market from September 1st, 2011 – You can order now!

The IC2 monoclonal autoantibody and its biotinylated, HRP, FITC and PE conjugated formats are planned to be commercial available from September 1st, 2011 after stability and quality control.  Antibody-online.com will on commission contract with ImmunoSigns do both marketing and sale, but the products will also be directly available from ImmunoSigns in Copenhagen directly from this […]

Preliminary biodistribution studies done in mice and rats

Using 125-I iodinated  tracers with both native IC2 – the IgM format -, and the pepsin digested F(ab’)2 and Fab fragments, plus in comparison two other beta-cell reactive monoclonals the mouse IgM A2B5, the mouse IgG K14D10, and an isotype Rat IgM control, its has been confirmed in biodistribution studies in both mice and rats, […]

In the search for the autoantigenic epitope for IC2 – is sulfatid CD1d complexes the target?

It has already been know for many year the the IC2 monoclonal autoantibodies sees epitipes located in socalled lipid rafts on the cell surface of the beta-cells. Studies by confocal laser fluorescence microscopy will now be supplement with studies aiming to characterize the exact epitope for the unique beta-cell specific autoantibodies.

The basic and clinical related research concerning IC2 and its autoantigen move from the Panum Institute, Department of Biomedical Sciences, to the new modern Copenhagen Biocenter at The Bartholin Institute

By action from September 1st 2010, the basic and clinically aiming research associated with the monoclonal autoantibody IC2 and its unique autoantigen specific on the surface of the pancreatic beta-cell, will move from University of Copenhagen, Department of Biomedical Sciences, to the new and modern Copenhagen Biocenter,  and be part of The Bartholin Institute, which […]

Large scale production of the genuin native IC2 monoclonal autoantibody has been initiated on contract with the Chech Republic biotech EXBIO

A large scale production of the native IgM IC2 monoclonal autoantibody is under execution on contact with the Chech Rebublicbiotech company EXBIO.

The EU-Fasilis programme supporting SME Biotech collaboration has granted ImmunoSigns with a Voucher

The European Commission initiative – the EU-FASILIS Programme – has funded ImmunoSigns with a Voucher to collaborate with Modiquest in Nijmegen for an expanded pilot production of recombinant and/or native fragmented IC2 monoclonal autoantibodies.

Recombinant chimeric humanised rhIC2-IgG

The IC2 monoclonal autoantibody has now been DNA cloned and expressed in various new formats including a chimeric humanized IgG format – this work has been done with support from International Juvenile Diabetes Research Foundation in the period 2008-10.

Diabetic animal model imaging of the pancreatic beta-cell mass

EU-”People” Research Training Program in Biotech and Bioethics aim to use IC2 non-invasive imaging of beta-cells mass in studies of induced chemeric immuno tolerence in animal moels of diabetes.

t-SNARE-complex beta-cell surface exposed epitopes might be involved in the functional state dependent IC2 autoantigen expression

Preliminary data with affinity crosslinking and flow cytometry indicate that proteins of the SNARE-cascade regulating the insulin excretion from beta-cells could be associated with the IC2 specific targeted epitope.